Evidence map›Paper›PMID 31396770›Full record

ArticleMolecular imaging and biology2020

Assessment of Chemotherapy-Induced Organ Damage with Ga-68 Labeled Duramycin.

Anne Rix, Natascha Ingrid Drude, Anna Mrugalla, Ferhan Baskaya, Koon Yan Pak, Brian Gray, Hans-Jürgen Kaiser, René Hany Tolba, Eva Fiegle, Wiltrud Lederle and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. EJNMMI research · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Anne RixInstitute for Experimental Molecular Imaging -Center for Biohybrid Medical Systems -CBMS, Medical Faculty, RWTH Aachen University, Forckenbeckstr. 55, 52074, Aachen, Germany.
Natascha Ingrid DrudeInstitute for Experimental Molecular Imaging -Center for Biohybrid Medical Systems -CBMS, Medical Faculty, RWTH Aachen University, Forckenbeckstr. 55, 52074, Aachen, Germany.
Anna MrugallaInstitute for Experimental Molecular Imaging -Center for Biohybrid Medical Systems -CBMS, Medical Faculty, RWTH Aachen University, Forckenbeckstr. 55, 52074, Aachen, Germany.
Ferhan BaskayaInstitute for Experimental Molecular Imaging -Center for Biohybrid Medical Systems -CBMS, Medical Faculty, RWTH Aachen University, Forckenbeckstr. 55, 52074, Aachen, Germany.
Koon Yan PakMolecular Targeting Technologies, Inc., West Chester, PA, USA.
Brian GrayMolecular Targeting Technologies, Inc., West Chester, PA, USA.
Hans-Jürgen KaiserDepartment for Nuclear Medicine -Uniklinik RWTH Aachen, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany.
René Hany TolbaInstitute for Laboratory Animal Science, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Eva FiegleInstitute for Experimental Molecular Imaging -Center for Biohybrid Medical Systems -CBMS, Medical Faculty, RWTH Aachen University, Forckenbeckstr. 55, 52074, Aachen, Germany.
Wiltrud LederleInstitute for Experimental Molecular Imaging -Center for Biohybrid Medical Systems -CBMS, Medical Faculty, RWTH Aachen University, Forckenbeckstr. 55, 52074, Aachen, Germany.
Felix Manuel MottaghyDepartment for Nuclear Medicine -Uniklinik RWTH Aachen, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany. fmottaghy@ukaachen.de.
Fabian KiesslingInstitute for Experimental Molecular Imaging -Center for Biohybrid Medical Systems -CBMS, Medical Faculty, RWTH Aachen University, Forckenbeckstr. 55, 52074, Aachen, Germany. fkiessling@ukaachen.de.ORCID http://orcid.org/0000-0002-7341-0399
RWTH Aachen University · DEMolecular Targeting Technologies (United States) · USUniversitätsklinikum Aachen · DEMaastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEvaluation of [ PROCEDURES: Tracer specificity of Ga-68 labeled NODAGA-duramycin was determined in vitro using competitive binding experiments. Organ uptake was analyzed in untreated and doxorubicin, busulfan, and cisplatin-treated mice 2 h after intravenous injection of [

resultsIn vitro experiments confirmed specific binding of [

conclusion[

Indexed as

BacteriocinsGallium RadioisotopesPeptidesAcetatesAnimalsAntineoplastic Combined Chemotherapy ProtocolsBusulfanCisplatinDoxorubicinFemaleHeterocyclic Compounds, 1-RingKidneyLiverMiceMice, Inbred BALB CNeoplasms1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononaneAcetatesBacteriocinsBusulfanCisplatinDoxorubicinduramycinGallium-68Gallium RadioisotopesHeterocyclic Compounds, 1-RingPeptidesRadiopharmaceuticalsApoptosisChemotherapyDuramycinPET/CTToxicity

Identifiers

PMID31396770
OpenAlexW2967999497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.